Similarly, we also found strong correlations of GSTM2 and GSTP1 promoter methylation with copy number alteration (CNA) burden in prostate cancer (Spearman’s ρ of 0.53 for GSTM2 and 0.49 for GSTP1; Supplementary Figure S7D and E), with both promoters among the promoters whose methylation is most strongly associated with CNA burden (Supplementary Figure S7F). The gene discussed is GSTP1; the disease is prostate carcinoma.